Literature DB >> 20088873

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.

Despina Handolias1, Renato Salemi, William Murray, Angela Tan, Wendy Liu, Amaya Viros, Alexander Dobrovic, John Kelly, Grant A McArthur.   

Abstract

In melanoma, mutations in KIT are most frequent in acral and mucosal subtypes and rarely reported in cutaneous melanomas particularly those associated with intermittent UV exposure. Conversely melanomas arising within chronic sun damaged skin are considered to harbour KIT mutations at higher rates. To characterize the frequency of KIT mutations in a representative melanoma population, 261 patients from two Australian melanoma centres were prospectively screened for mutations in exons 11, 13 and 17 of the KIT gene. A total of 257 patients had cutaneous melanoma arising from non-acral sites and four were acral melanomas. No mucosal or ocular melanomas were analysed. KIT mutations were identified in five tumours (2% of the entire cohort) including two acral melanomas. Two of the three non-acral melanomas with KIT mutations were associated with markers of chronic sun damage as assessed by the degree of skin elastosis. In the remaining cohort, 43% had chronically sun damaged skin. This report confirms that within an Australian population, KIT mutations are infrequent in cutaneous melanomas associated with both intermittent and chronic sun exposed skin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088873     DOI: 10.1111/j.1755-148X.2010.00671.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  41 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 4.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 5.  Advances in cutaneous melanoma.

Authors:  Enrique Espinosa; Alfonso Berrocal; José Antonio López Martín; María González Cao; Pablo Cerezuela; José Ignacio Mayordomo; Salvador Martín Algarra
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

6.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

7.  Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Piotr Waloszczyk; Marek Masiuk; Jaroslaw Wejman; Justyna Szumilo; Markku Miettinen
Journal:  Mod Pathol       Date:  2019-02-13       Impact factor: 7.842

Review 8.  Is UV an etiological factor of acral melanoma?

Authors:  Lin Liu; Weigang Zhang; Tianwen Gao; Chunying Li
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-10-14       Impact factor: 5.563

Review 9.  Update on the targeted therapy of melanoma.

Authors:  Douglas B Johnson; Jeffrey A Sosman
Journal:  Curr Treat Options Oncol       Date:  2013-06

10.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Authors:  D Handolias; A L Hamilton; R Salemi; A Tan; K Moodie; L Kerr; A Dobrovic; G A McArthur
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.